Why MSI-high cancers are more responsive to immune checkpoint inhibitors Annual Meeting GI 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses why MSI-high cancers are more responsive to immune checkpoint inhibitors at ASCO GI 2016